Overview

CARE Canadian ALS Riluzole Evaluation

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy of riluzole 50-mg bid defined by comparing the percentage of riluzole-treated subjects who experienced death, permanently assisted ventilation (PAV) or tracheostomy, to a group of recent historical controls for the treatment of amyotrophic lateral sclerosis (ALS).
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Riluzole